Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
Diabetes, Obesity and Metabolism · 2025-07 · 27 (7) · 3757-3765
DOI: 10.1111/dom.16401 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 05.05.2025. Verfasst von Emily R Hankosky und 7 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Obesity, Overweight. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Tirzepatide and semaglutide demonstrated clinically meaningful weight reduction in people with obesity or overweight and type 2 diabetes (T2D) in SURMOUNT‐2 and STEP 2 clinical trials, respectively. In the absence of head‐to‐head trials, this study compared the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison. Materials and Methods Mean percent change in weight from baseline, weight reduction ≥5% and mean change in glycated haemoglobin (HbA1c [%]) were compared between tirzepatide 10/15 mg (week 72, SURMOUNT‐2) and semaglutide 2.4 mg (week 68, STEP 2) applying the Bucher method to the efficacy estimand. Sensitivity analyses included the use of matching‐adjusted indirect comparison, treatment regimen estimand and comparing study outcomes at 68 weeks.
Results
Tirzepatide 10 and 15 mg were associated with significantly greater mean percent weight reductions versus semaglutide (mean difference, 10 mg: 2.57%; 15 mg: 4.79%, p < 0.01). Tirzepatide 15 mg had significantly higher odds of achieving ≥5% weight reduction (odds ratio 15 mg: 1.76, 95% CI 1.04–2.97, p = 0.035; odds ratio 10 mg: 1.24, 95% CI 0.75–2.04, p = 0.407), and both tirzepatide doses were associated with significantly greater reductions in HbA1c (%) levels (mean difference, 10 mg: 0.47%; 15 mg: 0.56%, p < 0.001) than semaglutide. Sensitivity analyses were generally consistent with the primary analysis, exceptions including when power was reduced in the matching‐adjusted indirect comparison analyses and in the categorical weight reduction outcome.
Conclusions
This analysis suggested greater reductions in bodyweight and HbA1c (%) levels associated with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg in people with obesity or overweight and T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: Emily R Hankosky, W Timothy Garvey
Förderung
- NIDDK NIH HHS
- Eli Lilly and Company
Zitieren
APA
Hankosky, E. R., He, X., Malik, R., Fraseur Brumm, J., Wang, F., Niemeyer, A., Zhang, X. M., & Garvey, W. T. (2025). Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison. Diabetes, Obesity and Metabolism, 27(7), 3757-3765. https://doi.org/10.1111/dom.16401
Vancouver
Hankosky ER, He X, Malik R, Fraseur Brumm J, Wang F, Niemeyer A, et al. Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison. Diabetes, Obesity and Metabolism. 2025;27(7):3757-3765. doi:10.1111/dom.16401
BibTeX
@article{Hankosky2025,
author = {Hankosky, Emily R and He, Xuanyao and Malik, Raleigh and Fraseur Brumm, Julia and Wang, Fangyu and Niemeyer, Anthony and Zhang, Xiaotian M and Garvey, W Timothy},
title = {Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {7},
pages = {3757--3765},
doi = {10.1111/dom.16401}
}
EUVIMED